ViewRay® to Participate in the B. Riley Securities Oncology Conference
ViewRay, Inc. (NASDAQ: VRAY) announced its participation in the B. Riley Securities Oncology Conference on January 28, 2022, at 1:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ViewRay, Inc. (NASDAQ: VRAY) announced its participation in the B. Riley Securities Oncology Conference on January 28, 2022, at 1:00 p.m. ET. CEO Scott Drake and CFO Zach Stassen will engage in a fireside chat during the event. Investors can access an audio webcast of the presentation on the investor relations section of the company's website, with a replay available for seven days post-event. ViewRay specializes in MR-guided radiation therapy with its MRIdian system, designed to enhance radiation oncology workflows.
Details
News Market Reaction – VRAY
The recorded move for VRAY in the trading session of this news was -1.12%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CLEVELAND, Jan. 25, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will participate in the B. Riley Securities Oncology Conference. Scott Drake, President and Chief Executive Officer, and Zach Stassen, Chief Financial Officer, will participate in a fireside chat at 1:00 p.m. Eastern Time on Friday, January 28, 2022.
An audio webcast of the Company's presentation will be available on the investor relations section of ViewRay's website at http://investors.viewray.com/events-and-presentations/upcoming-events. A replay of the webcast will be available for 7 days after the date of the presentation.
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
View original content:https://www.prnewswire.com/news-releases/viewray-to-participate-in-the-b-riley-securities-oncology-conference-301467337.html
SOURCE ViewRay, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.